Imaging software developer Median Technologies plans to highlight results of a study on the use of CT to monitor hepatocellular carcinoma lesions at the upcoming American Association for Cancer Research (AACR) annual meeting in New Orleans.
Hepatocellular carcinoma is the most common primary liver cancer, and in clinical trials, CT is widely used to monitor these patients.
The study investigated the causes of interreader variability in evaluating the therapeutic response of hepatocellular carcinoma when relying on a modified Response Evaluation Criteria in Solid Tumors (mRECIST) protocol. Researchers found that the modified procedure is best handled by experienced clinicians, and that a second reading is recommended, Median said.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)